Research shows that combination therapy for malignancies has substantial risk of cardiac problems. In 2009, an article was published on Medscape showed that these cardiac problems include congestive heart failure, myocardial infarction (MI), pericardial disease or abnormalities of the heart valves.
The study recommended that cardiologists work with oncologists to determine cardiovascular risk based on the toxicities of the drugs used in chemotherapy trials.
In 2010, in the Journal of Cancer Institute an article called on oncologists to be fully aware of the cardio toxicity of anti-cancer drugs, concluding that these agents all affect microenvironment while not affecting the tumor. It was concluded that combination therapy amplifies the toxic effects of the drugs, with radiotherapy causing heart problems. A call was made for a new discipline, cardio-oncology or onco-cardiology to determine the choice of therapy to lessen the risk that the cancer patient would soon become a heart patient.
Unfortunately, women treated with radiation for breast cancer also have an increased risk of cardiovascular disease, proportional to the amount of radiation to which the heart is exposed. The risk begins a few years after exposure and continues for at least 20 years. More than half the heart attacks occur in people with few “risk factors.” Houston Chronicle, Jan. 10, 1998.
Oncologist need to know that before treating patients with radiation, treat them prophylactically with PEOs at least two weeks before and two weeks after treatment to significantly stop the radiation damage.
PEOs protect the cardiovascular system in patients undergoing any type of cancer therapy, positively assisting cancer patient mortality and increasing positive outcomes from therapy. PEOs are the ideal adjuvant to any oncology protocol.
Mike Maunu – Founder
Oxygen4Life.com
